Metzincin | Physiological function | Postinjury function |
---|---|---|
MMP-2 | Neurite outgrowthc | Axonal regeneration and tissue repairc |
Astrocyte motilityb | ||
PNS myelinationb | ||
MMP-3 | Neurite outgrowthc | |
Neural cell survivalc | ||
MMP-7 | Neurotrophin convertasea | |
MMP-9 | Neurite outgrowthc | Excitotoxic neuronal deathc |
Neural cell precursor migrationc and survivala | Scar formationc | |
Oligodendrocyte maturation and myelinationc | Remyelinationa | |
NGF degradationa | Neural cell precursor mobilizationc | |
MMP-12 | Oligodendrocyte maturation and myelinationc | Secondary damage in SCIc |
MMP-24 | Spinal cord axonal sproutingc | |
MT–MMPs | Neuroblast migrationb | |
ADAM-10 | Axonal extension,a guidance,a and stabilizationc | |
Neuronal migration and differentiationa | ||
ADAM-17 | Neurite outgrowth in the presence of myelin ligandsc | |
ADAMTS-4 | Neurite outgrowtha | |
ADAMTS-5 | Neurite outgrowtha |
↵Findings have been obtained mostly with amolecular,
↵bpharmacological, or
↵cboth molecular and pharmacological approaches. Pharmacological approaches essentially use metzincin inhibitors, whereas molecular approaches include the use of recombinant metzincins or gain–loss-of-function engineered molecules.
SCI, Spinal cord injury; NGF, nerve growth factor; PNS, peripheral nervous system.